Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo H Paredes

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
The Annals of Pharmacotherapy|April 12, 2007
Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infectionAngelo H Paredes, James H Lewis
Current Gastroenterology Reports|September 19, 2025
Portal Hypertensive Colopathy: Diagnostic Challenges and Management in CirrhosisJiasheng Henry Guo, Angelo H Paredes
Current Opinion in Gastroenterology|April 15, 2008
Drug-induced liver injury in 2007William Norris, Angelo H Paredes, James H Lewis
Clinical Liver Disease|June 13, 2019
Treatment of nonalcoholic fatty liver disease: Role of dietary modification and exerciseAngelo H Paredes, Dawn M Torres, Stephen A Harrison
Clinics in Liver Disease|May 1, 2012
Nonalcoholic fatty liver diseaseAngelo H Paredes, Dawn M Torres, Stephen A Harrison
Plos One|July 11, 2019
Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosisSumit Kar, Sabina Paglialunga, Sharon H Jaycox, et al.
The Korean Journal of Gastroenterology = Taehan Sohwagi Hakhoe Chi|September 27, 2021
Early Cardiac Dysfunction in Biopsy-proven Nonalcoholic Fatty Liver DiseasePeter C Johnson, Anthony A Cochet, Rosco S Gore, et al.
Plos One|September 8, 2018
Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trialStephen A Harrison, Andrea Dennis, Martine M Fiore, et al.
Journal of Hepatology|December 12, 2018
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitisMary E Rinella, James F Trotter, Manal F Abdelmalek, et al.
Hepatology (Baltimore, Md.)|February 27, 2019
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic SteatohepatitisStephen A Harrison, Stephen J Rossi, Angelo H Paredes, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
The Annals of Pharmacotherapy|April 12, 2007
Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infectionAngelo H Paredes, James H Lewis
Current Gastroenterology Reports|September 19, 2025
Portal Hypertensive Colopathy: Diagnostic Challenges and Management in CirrhosisJiasheng Henry Guo, Angelo H Paredes
Current Opinion in Gastroenterology|April 15, 2008
Drug-induced liver injury in 2007William Norris, Angelo H Paredes, James H Lewis
Clinical Liver Disease|June 13, 2019
Treatment of nonalcoholic fatty liver disease: Role of dietary modification and exerciseAngelo H Paredes, Dawn M Torres, Stephen A Harrison
Clinics in Liver Disease|May 1, 2012
Nonalcoholic fatty liver diseaseAngelo H Paredes, Dawn M Torres, Stephen A Harrison
Plos One|July 11, 2019
Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosisSumit Kar, Sabina Paglialunga, Sharon H Jaycox, et al.
The Korean Journal of Gastroenterology = Taehan Sohwagi Hakhoe Chi|September 27, 2021
Early Cardiac Dysfunction in Biopsy-proven Nonalcoholic Fatty Liver DiseasePeter C Johnson, Anthony A Cochet, Rosco S Gore, et al.
Plos One|September 8, 2018
Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trialStephen A Harrison, Andrea Dennis, Martine M Fiore, et al.
Journal of Hepatology|December 12, 2018
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitisMary E Rinella, James F Trotter, Manal F Abdelmalek, et al.
Hepatology (Baltimore, Md.)|February 27, 2019
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic SteatohepatitisStephen A Harrison, Stephen J Rossi, Angelo H Paredes, et al.
Pageof 2